Evidence map›Paper›PMID 42869577›Full record

ArticleJournal for immunotherapy of cancer2026

Affinity-optimized bispecific CAR-T cells targeting HLA-G and CD70 for the treatment of clear cell renal cell carcinoma.

Lianpan Su, Xiaodan Ma, Dawei Chen, Weiyi Wang, Weiliang Yang, Siwei Huang, Yuqian Pang, Shuzhen Chen, Limin Cheng, Chaochao Bian and 4 more

Abstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lianpan Su *State Key Laboratory of Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.ORCID http://orcid.org/0009-0001-2298-1669
Xiaodan Ma *State Key Laboratory of Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Dawei Chen *Institute of Blood Transfusion, Guangzhou Blood Center, Guangzhou, Guangdong, China.
Weiyi Wang *State Key Laboratory of Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Weiliang YangState Key Laboratory of Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Siwei HuangState Key Laboratory of Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Yuqian PangState Key Laboratory of Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Shuzhen ChenState Key Laboratory of Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Limin ChengGuangzhou FineImmune Biotechnology Co., LTD, Guangzhou, Guangdong, China.
Chaochao BianGuangzhou FineImmune Biotechnology Co., LTD, Guangzhou, Guangdong, China.
Jianeng ZhangState Key Laboratory of Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Ziqian FangState Key Laboratory of Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Xiaomin ZhangState Key Laboratory of Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China zhouph@sysucc.org.cn Zhangxm@sysucc.org.cn.
Penghui ZhouState Key Laboratory of Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China zhouph@sysucc.org.cn Zhangxm@sysucc.org.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Chimeric antigen receptor - CARKidney CancerSolid tumorT cell

Identifiers

PMID42869577
PMCPMC13663753

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.